RankAlpha logo
Back to Rankings

ADMA

ADMA BiologicsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The constructive read is that Q1 exposed a temporary channel and pricing reset rather than a demand break: ASCENIV grew 28% year over year, gross margin reached 71%, and operating cash flow was $58 million, while management said April demand tracked first-quarter direct sales and called Q1 a likely trough baseline [#8-K-2026-05-06].
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.3.
What can break
ADMA remains highly dependent on ASCENIV staying insulated from broader IG pricing pressure; if ASCENIV demand or pricing weakens, the trough-recovery thesis breaks.
Momentum
15
Value
67
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.90 · Bull $12.50 · Bear $6.50
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum15 · Δ7d -6.7
Value67 · Δ7d +0.3
Sentiment56 · Δ7d -0.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
15
26% active weight
Current posture
7d trendSoftening
Δ7d
-6.7
Δ21d
+9.4
Value
67
39% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
-0.3
Sentiment
56
34% active weight
Current posture
7d trendFlat
Δ7d
-0.8
Δ21d
-8.9
Why this grade

Composite grade C. Momentum 14.8 / Value 66.6 / Sentiment 56.4

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.99B
Beta
0.49
Shares Out
231.77M
P/E (TTM)
21.3
P/S (TTM)
8.78
P/FCF (TTM)
105.67
Rev YoY
-0.3%
EPS YoY
+71.7%
Gross Margin
+61.2%
Op Margin
+33.2%
Net Debt
-$7.75M
Current Ratio
6.95
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology